568 related articles for article (PubMed ID: 12835715)
21. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.
Chu S; McDonald T; Bhatia R
Leukemia; 2010 Apr; 24(4):779-87. PubMed ID: 20200561
[TBL] [Abstract][Full Text] [Related]
22. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
23. Integration of molecular and biological abnormalities in quest for selective treatment of chronic myelogenous leukemia (CML).
Clarkson B; Strife A; Perez A; Lambek C; Wisniewski D
Leuk Lymphoma; 1993; 11 Suppl 2():81-100. PubMed ID: 8124237
[TBL] [Abstract][Full Text] [Related]
24. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia.
Holyoake TL; Jiang X; Drummond MW; Eaves AC; Eaves CJ
Leukemia; 2002 Apr; 16(4):549-58. PubMed ID: 11960331
[TBL] [Abstract][Full Text] [Related]
25. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo.
Zhao RC; McIvor RS; Griffin JD; Verfaillie CM
Blood; 1997 Dec; 90(12):4687-98. PubMed ID: 9389683
[TBL] [Abstract][Full Text] [Related]
26. Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles.
Ramos TL; Sánchez-Abarca LI; López-Ruano G; Muntión S; Preciado S; Hernández-Ruano M; Rosado B; de las Heras N; Chillón MC; Hernández-Hernández Á; González M; Sánchez-Guijo F; Del Cañizo C
Leuk Res; 2015 Aug; 39(8):921-4. PubMed ID: 26105049
[TBL] [Abstract][Full Text] [Related]
27. High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration.
Petzer AL; Hochenburger E; Haun M; Duba HCh; Grünewald K; Hoflehner E; Sill H; Linkesch W; Gastl G; Gunsilius E
J Hematother Stem Cell Res; 2002 Apr; 11(2):293-300. PubMed ID: 11983100
[TBL] [Abstract][Full Text] [Related]
28. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.
Era T; Witte ON
Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1737-42. PubMed ID: 10677527
[TBL] [Abstract][Full Text] [Related]
29. Growth autonomy and lineage switching in BCR-ABL-transduced human cord blood cells depend on different functional domains of BCR-ABL.
Chalandon Y; Jiang X; Loutet S; Eaves AC; Eaves CJ
Leukemia; 2004 May; 18(5):1006-12. PubMed ID: 15014528
[TBL] [Abstract][Full Text] [Related]
30. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
Bhatia R; Munthe HA; Verfaillie CM
Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
[TBL] [Abstract][Full Text] [Related]
31. [History of chronic myeloid leukemia: a paradigm in the treatment of cancer].
Gonon-Demoulian R; Goldman JM; Nicolini FE
Bull Cancer; 2014 Jan; 101(1):56-67. PubMed ID: 24491668
[TBL] [Abstract][Full Text] [Related]
32. The effect of Bcr-Abl protein tyrosine kinase on maturation and proliferation of primitive haematopoietic cells.
Buckle AM; Mottram R; Pierce A; Lucas GS; Russell N; Miyan JA; Whetton AD
Mol Med; 2000 Oct; 6(10):892-902. PubMed ID: 11126203
[TBL] [Abstract][Full Text] [Related]
33. Chronic myeloid leukemia stem cells.
Jamieson CH
Hematology Am Soc Hematol Educ Program; 2008; ():436-42. PubMed ID: 19074122
[TBL] [Abstract][Full Text] [Related]
34. Evolving molecular therapy for chronic myeloid leukaemia--are we on target?
Copland M; Jørgensen HG; Holyoake TL
Hematology; 2005 Oct; 10(5):349-59. PubMed ID: 16203604
[TBL] [Abstract][Full Text] [Related]
35. Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?
Verfaillie CM; Hurley R; Lundell BI; Zhao C; Bhatia R
Acta Haematol; 1997; 97(1-2):40-52. PubMed ID: 8980609
[TBL] [Abstract][Full Text] [Related]
36. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia.
Bedi A; Zehnbauer BA; Collector MI; Barber JP; Zicha MS; Sharkis SJ; Jones RJ
Blood; 1993 Jun; 81(11):2898-902. PubMed ID: 8499629
[TBL] [Abstract][Full Text] [Related]
37. BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic myeloid leukemia patients.
Grand FH; Marley SB; Chase A; Titley I; Healy L; Spencer A; Reiter A; Goldman JM; Gordon MY
Leukemia; 1997 Sep; 11(9):1486-92. PubMed ID: 9305602
[TBL] [Abstract][Full Text] [Related]
38. BCR/ABL induces multiple abnormalities of cytoskeletal function.
Salgia R; Li JL; Ewaniuk DS; Pear W; Pisick E; Burky SA; Ernst T; Sattler M; Chen LB; Griffin JD
J Clin Invest; 1997 Jul; 100(1):46-57. PubMed ID: 9202056
[TBL] [Abstract][Full Text] [Related]
39. The biology of normal and neoplastic stem cells in CML.
Eaves C; Udomsakdi C; Cashman J; Barnett M; Eaves A
Leuk Lymphoma; 1993; 11 Suppl 1():245-53. PubMed ID: 8251904
[TBL] [Abstract][Full Text] [Related]
40. Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors.
Bhatia R; Munthe HA; Verfaillie CM
Exp Hematol; 1999 Sep; 27(9):1384-96. PubMed ID: 10480429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
